Johnson & Johnson Secures FDA Approval for Oral IL-23 Psoriasis Pill Achieving 70% Clearance
FDA approved ICOTYDE, a once-daily oral IL-23 receptor antagonist for adults and adolescents with moderate-to-severe plaque psoriasis, based on ICONIC Phase 3 trials. About 70% of patients achieved clear or almost clear skin and 55% reached PASI 90 by Week 16, with adverse reactions within 1.1% of placebo.
1. FDA Approval of ICOTYDE
The U.S. Food and Drug Administration approved ICOTYDE (icotrokinra) as the first targeted oral IL-23 receptor antagonist for adults and adolescents aged 12 and older weighing at least 40 kg with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.
2. ICONIC Phase 3 Trial Outcomes
The pivotal ICONIC clinical program enrolled approximately 2,500 patients across four Phase 3 trials, with around 70% achieving clear or almost clear skin (IGA 0/1) and 55% reaching PASI 90 by Week 16. Adverse reaction rates were within 1.1% of placebo through Week 16 and no new safety signals emerged through Week 52.
3. Market Potential and Unmet Need
Psoriasis affects over 8 million Americans, many of whom require systemic treatment after unsuccessful topical therapy. The oral, once-daily format and targeted mechanism address an unmet need for patients transitioning to systemic options under current treatment guidelines.
4. Commercial Strategy and Patient Support
Johnson & Johnson plans to launch ICOTYDE with a comprehensive support program offering cost assistance, nurse guides and educational resources to streamline patient access regardless of insurance status.